Moderna MRNA 深 滬
已收盤 08-01 16:00:00 美东时间
27.605
-1.955
-6.61%
華盛通- 最 高27.88
- 今 開27.57
- 成交量 1628.15万股
- 最 低 26.5648
- 昨 收 29.56
- 總市值 106.83亿
- 52周最高 91.99
- 市盈率 靜 --
- 換手率 4.21%
- 52周最低 23.15
- 委 比 -95.18%
- 總股本 3.87亿
- 歷史最高 497.49
- 量 比 2.04
- 振 幅 4.45%
- 歷史最低 11.54
- 每 手 1
- 風險率 18.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Moderna’s Earnings Call: A Mix of Gains and Challenges
Moderna (($MRNA)) has held its Q2 earnings call. Read on for the main highlight...
今天 09:22
Allogene Resets Clinical Course After Patient Death In Lymphoma Study
Allogene revised its LBCL trial after a fatal adverse event linked to ALLO-647, shifting to a standard FC regimen and updating its clinical approach.
今天 00:52
Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector
Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results.
08-01 23:32
莫德纳股价下跌，因英国疫苗交付延迟下调营收预期
莫德纳股价今年已跌超三分之一。 莫德纳（MRNA）股价周五大幅下跌，原因是该公司因向英国交付疫苗延迟，下调了全年营收预期的上限。 这家总部位于马萨诸...
08-01 23:20
美股异动丨莫德纳(MRNA.US)大跌超10%，下调2025年收入预期上限
格隆汇8月1日｜Moderna(MRNA.US)盘中一度跌超10%，报26.56美元。公司公布第二季净亏损8.25亿美元，每股亏损2.13美元，低于预期的亏损...
08-01 23:17
Experts helping vaccine advisors are reportedly ousted at CDC
The CDC has informed public health experts and physician organizations, whose views are considered in shaping the U.S. vaccine policy, that their services are no longer required for a key vaccine advi...
08-01 23:07
MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
Shares in drug giant Moderna (MRNA) plummeted nearly 10% today after it reporte...
08-01 23:02
非农数据遭遇“暴力下修” 欧美股市集体走弱 | 今夜看点
1、7月美国非农就业数据不及预期，前两个月更是被砍到只剩零头；2、美国降息预期升温，美股期指、美元走弱，黄金拉升；3、指引逊于预期，亚马逊盘前跳水；4、消息称美国联邦医保正考虑试点覆盖减肥药物。
08-01 21:05
Moderna shares are trading lower following the release of its Q2 financial results.
Moderna shares are trading lower following the release of its Q2 financial resu...
08-01 20:50
Moderna's Key Patent Win Overshadowed By Gloomy Outlook
Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce.
08-01 20:44
